Pfizer Publishes Q3 2026 Earnings Call Transcript

Bitget2026/11/03 22:16

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Pfizer raised full-year 2026 revenue guidance to $62 billion-$64 billion, up $1.5 billion at the midpoint.
Adjusted diluted EPS guidance increased to $2.95-$3.05, incorporating a $0.10-per-share charge from the Innovent transaction.
Third-quarter revenue reached $16.6 billion; adjusted diluted EPS totaled $0.87.
Management expects nearly $7.2 billion in net savings by year-end, with another $2.5 billion targeted for 2027-2029.
The November 3 earnings call included CEO Albert Bourla, CFO Cecile Guegan and R&D chief Chris Boshoff.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Pfizer Publishes Q3 2026 Earnings Call Transcript

You may also like

Crypto prices